This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2024
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2024 | 990 | $2,431,187 | $2,589,586 | $1,807,000 | $10,302,865 | $8,525,880 |
| FY2023 | 990 | $1,711,550 | $2,185,452 | $1,434,781 | $10,046,196 | $8,111,918 |
| FY2022 | 990 | $3,012,671 | $1,718,648 | $992,500 | $8,969,682 | $7,417,407 |
| FY2021 | 990 | $2,826,481 | $1,990,023 | $1,270,469 | $8,993,790 | $7,025,774 |
| FY2020 | 990 | $2,160,688 | $2,016,337 | $1,353,855 | $8,297,280 | $6,810,379 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 31% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| CHILDREN'S HOSPITAL LOS ANGELES USCLOS ANGELES, CA | FLIP-FLOPPING OF FUSION-POSITIVE RHABDOMYOSARCOMA LEADING TO METASTATIC INVASION | $225,000 | 2023 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| CHILDRENS HOSPITAL LOS ANGELESLOS ANGELES, CA |
| NOVEL MOLECULAR MECHANISM(S) OF P1D1 FUNCTION IN PEDIATRIC BRAIN TUMORS. |
| $150,000 |
| 2024 |
| UNIVERSITY OF SOUTHERN CALIFORNIALOS ANGELES, CA | ETHNIC DIFFERENCES AMONG BREAST CANCER PATIENT IMMUNE RESPONSES | $100,000 | 2023 |
| UNIVERSITY OF SOUTHERN CALIFORNIALOS ANGELES, CA | RESEARCH INTO ETHNIC DIFFERENCES AMONG BREAST CANCER PATIENT IMMUNE RESPONSES | $100,000 | 2022 |
| USC NORRIS COMPREHENSIVE CANCER CENTERLOS ANGELES, CA | ETHNIC DIFFERENCES IN IMMUNE RESPONSES AMONG BREAST CANCER PATIENTS | $100,000 | 2024 |
| CHILDREN'S HOSPITAL LOS ANGELESLOS ANGELES, CA | SUMMER ONCOLOGY RESEARCH FELLOWSHIP PROGRAM | $90,000 | 2024 |
| CHILDREN'S HOSPITAL LOS ANGELESLOS ANGELES, CA | Novel Molecular Mechanisms of P1D1 function in Pediatric Brain Tumors | $87,500 | 2020 |
| OHIO STATE UNIVERSITYCOLUMBUS, OH | TARGETING A NEW IMMUNE CHECKPOINT AXIS (PILRCD8) TO TREAT GLIOBLASTOMA | $75,000 | 2024 |
| UT MD ANDERSON CANCER CENTERHOUSTON, TX | ELUCIDATING THE MOLECULAR AND CELLULAR PATHOGENESIS OF ENDOGENOUS RETROVIRUSES IN SKIN CANCER | $75,000 | 2024 |
| CHILDREN'S HOSPITAL LOS ANGELESLOS ANGELES, CA | ELUCIDATING THE MECHANISM OF CHROMOSOME 17Q GAIN-MEDIATED NEUROBLASTOMA TUMORIGENESIS | $75,000 | 2024 |
| THE WISTAR INSTITUTEPHILADELPHIA, PA | MYELOID CELL-DERIVED INTERLEUKIN 1B PROMOTES CHEMORESISTANCE IN METASTATIC OVARIAN CANCER. | $75,000 | 2024 |
| WASHINGTON UNIVERSITYST LOUIS, MO | TARGETING MECHANISMS OF TUMOR IMMUNE EVASION IN CERVICAL CANCER | $75,000 | 2024 |
| OREGON HEALTH AND SCIENCE UNIVERSITYPORTLAND, OR | REPROGRAMMING SUPPRESSIVE REGULATORY T CELLS IN THE TUMOR MICROENVIRONMENT | $75,000 | 2024 |
| TEMPLE UNIVERSITYPHILADELPHIA, PA | ROLE OF CHEMOTHERAPY IN PROMOTING AWAKENING OF DORMANT TUMOR CELLS AND METASTATIC RELAPSE | $75,000 | 2024 |
| OREGON HEALTH & SCIENCE UNIVERSITYPORTLAND, OR | ANTIGEN SORTING BY DENDRITIC CELLS IMPACTS ANTI-TUMOR IMMUNITY | $75,000 | 2024 |
| UNIVERSITY OF CA LOS ANGELESLOS ANGELES, CA | Identification and Functional Characterization of Kinases Driving Prostate Cancer Metastasis to Bone. | $75,000 | 2020 |
| THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTERHOUSTON, TX | TARGETING COLLAGEN I HOMOTRIMER INDUCED IL-18 AS A NOVEL THERAPEUTIC STRATEGY IN PANCREATIC CANCER | $75,000 | 2024 |
| MEMORIAL SLOAN KETTERING CANCER CENTERNEW YORK, NY | EARLY TRANSCRIPTIONAL, EPIGENETIC, AND ENVIRONMENTAL FACTORS OF SQUAMOUS TRANSFORMATION IN LUNG CANCER | $75,000 | 2024 |
| UNIVERSITY OF ROCHESTERROCHESTER, NY | MECHANISMS UNDERLYING NEAT1 FUNCTION IN PRESERVING THE IDENTITY OF PANCREATIC CELLS | $60,000 | 2021 |
| UNIVERSITY OF MICHIGANANN ARBOR, MI | REGULATING JAK-STAT SIGNALING PATHWAYS TO ENHANCE T CELL IMMUNOTHERAPY | $60,000 | 2023 |
| BECKMAN RESEARCH INSTITUTE OF CITY OF HOPEDUARTE, CA | TARGETING THE LONG ISOFORM OF THE PROLACTIN RECEPTOR IN B CELL MALIGNANCIES | $60,000 | 2023 |
| MASSACHUSETTS GENERAL HOSPITALSOMERVILLE, MA | TARGETING FATTY ACID BIOSYNTHESIS IN GLIOBLASTOMA | $60,000 | 2021 |
| CHILDREN'S HOSPITAL LOS ANGELES USCLOS ANGELES, CA | FLIP-FLOPPING OF FUSION-POSITIVE RHABDOMYOSARCOMA LEADING TO METASTATIC INVASION | $60,000 | 2022 |
| PURDUE UNIVERSITYWEST LAFAYETTE, IN | THE ROLE OF PP2A IN REGULATING PDAC METHUOSIS | $60,000 | 2023 |
| PURDUE UNIVERSITYWEST LAFAYETTE, IN | THE ROLE OF PP2A IN REGULATING PDAC METHUOSIS | $60,000 | 2022 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202432969349301333
Form 990 · FY2022 · period ending Dec 31, 2022
Filing id 202332429349301353
Form 990 · FY2021 · period ending Dec 31, 2021
Filing id 202203009349300000
Form 990 · FY2020 · period ending Dec 31, 2020
Filing id 202143149349301639
Form 990 · FY2019 · period ending Dec 31, 2019
Filing id 202023189349309887
Form 990 · FY2018 · period ending Dec 31, 2018
Filing id 201903169349303110
Form 990 · FY2017 · period ending Dec 31, 2017
Filing id 201812849349300536
Form 990 · FY2016 · period ending Dec 31, 2016
Filing id 201733199349315833
Form 990 · FY2015 · period ending Dec 31, 2015
Filing id 201603209349313445
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.